Prescient Therapeutics Limited (ASX:PTX)
0.0500
-0.0010 (-1.96%)
Apr 20, 2026, 3:54 PM AEST
Prescient Therapeutics Revenue
Prescient Therapeutics had revenue of 1.16M AUD in the half year ending December 31, 2025, a decrease of -40.31%. This brings the company's revenue in the last twelve months to 4.27M, up 41.20% year-over-year. In the fiscal year ending June 30, 2025, Prescient Therapeutics had annual revenue of 4.36M with 17.35% growth.
Revenue (ttm)
4.27M
Revenue Growth
+41.20%
P/S Ratio
12.33
Revenue / Employee
1.42M
Employees
3
Market Cap
52.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 4.36M | 644.03K | 17.35% |
| Jun 30, 2024 | 3.71M | 1.28M | 52.89% |
| Jun 30, 2023 | 2.43M | 538.79K | 28.52% |
| Jun 30, 2022 | 1.89M | 703.86K | 59.37% |
| Jun 30, 2021 | 1.19M | 156.14K | 15.17% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 61.40M |
| Radiopharm Theranostics | 16.28M |
| Neurizon Therapeutics | 5.98M |
| Amplia Therapeutics | 5.01M |
| Imugene | 3.94M |
| Proteomics International Laboratories | 3.21M |
| Cynata Therapeutics | 1.69M |
| Entropy Neurodynamics | 1.58M |